ArticleFrontiers in immunology2026
Dysfunctional decidual CD2
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maternal-fetal interface abnormalities in unexplained recurrent pregnancy loss: mechanisms, models, and a framework for subtype identification.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The multifactorial nature of recurrent pregnancy loss (RPL) requires a comprehensive understanding of its diverse risk factors, including sleep disturbance. Previously, we reported decreased Rev-erbα expression in decidual stromal cells from pregnant mice with sleep disturbance (SD) and patients of RPL with sleep disturbance (RS). Methods: Omics analyses were used to predict the interaction between Rev-erbα and glutamine-fructose-6-phosphate amidotransferase 1 (GFPT1). Tunicamycin and peptide-N-glycosidase F and phosphatidylinositol-specific phospholipase C treatment were conducted to analyze the glycosylation modification type of CD58. The coculture between decidual immune cells and decidual stroma cells (DSCs) in which Rev-erbα, GFPT1, or CD58 was either knockdown or overexpressed was performed to evaluate the crosstalk of CD58 Results: We found that glycometabolism related GFPT1, which regulated by Rev-erbα, increased CD58 expression via glycosylphosphatidylinositol modification not classical N- or O-linked glycosylation modification, leading to the disorder of decidual CD2 Conclusions: Rev-erbα - GFPT1 - CD58 - CD2 axis played important role in pregnancy maintenance by regulating the crosstalk between DSCs and decidual CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.